Smallpox vaccines: current and future (Q35587865)

9 August 2017

1 reference

title

Smallpox vaccines: current and future (English)

1 reference

9 August 2017

1 reference

2

Gregory A Poland

1 reference

9 August 2017

Ruben Bonilla-Guerrero

series ordinal

1

1 reference

9 August 2017

1 October 2003

1 reference

9 August 2017

Translational Research

1 reference

9 August 2017

142

1 reference

9 August 2017

4

1 reference

9 August 2017

252-257

1 reference

Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

The looming threat of bioterrorism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Global Eradication of Smallpox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

New smallpox case seems lab-caused

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Clinical responses to undiluted and diluted smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Stability of Undiluted and Diluted Vaccinia‐Virus Vaccine, Dryvax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Response to smallpox vaccine in persons immunized in the distant past

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Smallpox vaccination: Risk considerations for patients with atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Complications of smallpox vaccination, 1968.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Smallpox vaccination in 2003: key information for clinicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Developing new smallpox vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

The age-dependent risk of postvaccination complications in vaccinees with smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

From the Centers for Disease Control and Prevention. Update: adverse events following smallpox vaccination--United States, 2003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

From the Centers for Disease Control and Prevention. Supplemental recommendations on adverse events following smallpox vaccine in the pre-event vaccination program: recommendations of the Advisory Committee on Immunization Practices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Diagnosis and management of smallpox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Immunologic responses to vaccinia vaccines administered by different parenteral routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Immunogenetic mechanisms of antibody response to measles vaccine: the role of the HLA genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Epitope dominance, competition and T cell affinity maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Epitope affinity for MHC class I determines helper requirement for CTL priming.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

The role of mass spectrometry in vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

Advances in proteome analysis by mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2803%2900143-4

10.1016/S0022-2143(03)00143-4

7 January 2021

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14625531